Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication.
Altin SE, Parise H, Hess CN, Rosenthal NA, Creager MA, Aronow HD, Curtis JP.
JACC Cardiovasc Interv. 2023 Jul 10;16(13):1668-1678. doi: 10.1016/j.jcin.2023.05.001.
Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication.
Kinlay S.
JACC Cardiovasc Interv. 2023 Sep 25;16(18):2335. doi: 10.1016/j.jcin.2023.08.002.
Reply: Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication.
Altin SE, Curtis JP.
JACC Cardiovasc Interv. 2023 Sep 25;16(18):2336. doi: 10.1016/j.jcin.2023.08.027.
Clinical practice. Intermittent claudication.
White C.
N Engl J Med. 2007 Mar 22;356(12):1241-50. doi: 10.1056/NEJMcp064483.
Treating complex femoropopliteal lesions.
van der Vijver-Coppen RJ, 't Mannetje YW, Menting TP, Lardenoije JW, Reijnen MP.
J Cardiovasc Surg (Torino). 2018 Apr;59(2):158-163. doi: 10.23736/S0021-9509.18.10374-0. Epub 2018 Jan 9.
Phosphodiesterases as targets for intermittent claudication.
Liu Y, Shakur Y, Kambayashi J.
Handb Exp Pharmacol. 2011;(204):211-36. doi: 10.1007/978-3-642-17969-3_9.
Intermittent claudication.
Strandness DE Jr.
Cardiovasc Clin. 1971;3(1):53-63.
Outcomes of axillofemoral and aortofemoral bypass for intermittent claudication may be similar.
Samson RH.
J Vasc Surg. 2022 May;75(5):1695. doi: 10.1016/j.jvs.2021.12.049.
Management of peripheral arterial disease and intermittent claudication.
Schainfeld RM.
J Am Board Fam Pract. 2001 Nov-Dec;14(6):443-50.
A Rare Cause of Intermittent Claudication: Persistent Sciatic Artery.
Kretzschmar D, Möbius-Winkler S.
Dtsch Arztebl Int. 2021 May 28;118(21):362. doi: 10.3238/arztebl.m2021.0106.
